Revolution Medicines, Inc. Interest Expense
Revolution Medicines, Inc. (RVMD) reported Interest Expense of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2023-02-27
- Revolution Medicines, Inc. interest expense for the quarter ending 2022-12-31 was $0.00.
- Revolution Medicines, Inc. interest expense for the quarter ending 2022-09-30 was $0.00.
- Revolution Medicines, Inc. interest expense for the quarter ending 2022-06-30 was $0.00.
- Revolution Medicines, Inc. interest expense for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Revolution Medicines, Inc. interest expense for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Revolution Medicines, Inc. interest expense for fiscal 2021 was $12.00K, a 83.10% decline from fiscal 2020.
- Revolution Medicines, Inc. interest expense for fiscal 2020 was $71.00K, a 33.02% decline from fiscal 2019.
- Revolution Medicines, Inc. interest expense for fiscal 2019 was $106.00K, a 8.62% decline from fiscal 2018.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $0.00 10-K · filed 2023-02-27 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | $0.00 derived: sum of 4 quarters · filed 2023-02-27 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $0.00 derived: sum of 4 quarters · filed 2023-02-27 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-09 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $0.00 derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $0.00 derived: sum of 3 quarters · filed 2023-02-27 | $12.00K 10-K · filed 2023-02-27 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $12.00K 10-Q · filed 2022-11-07 | $26.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | $12.00K 10-Q · filed 2022-08-09 | $26.00K derived: sum of 3 quarters · filed 2023-02-27 | $43.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $12.00K 10-Q · filed 2022-05-09 | $26.00K derived: sum of 2 quarters · filed 2023-02-27 | $43.00K derived: sum of 3 quarters · filed 2023-02-27 | $62.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $31.00K derived: sum of 2 quarters · filed 2023-02-27 | $50.00K derived: sum of 3 quarters · filed 2023-02-27 | $71.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $17.00K 10-Q · filed 2021-11-10 | $36.00K derived: sum of 2 quarters · filed 2021-11-10 | $57.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $19.00K 10-Q · filed 2021-08-11 | $40.00K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $21.00K 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $106.00K 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $116.00K 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |